Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Construction in Progress (2021 - 2023)

SAB Biotherapeutics (SABS) has disclosed Construction in Progress for 2 consecutive years, with $84739.0 as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Construction in Progress fell 38.51% year-over-year to $84739.0, compared with a TTM value of $84739.0 through Dec 2022, down 38.51%, and an annual FY2022 reading of $84739.0, down 38.51% over the prior year.
  • Construction in Progress was $84739.0 for Q4 2022 at SAB Biotherapeutics, down from $137811.0 in the prior quarter.
  • Across five years, Construction in Progress topped out at $137811.0 in Q4 2021 and bottomed at $84739.0 in Q4 2022.